Market revenue in 2020 | USD 50.6 million |
Market revenue in 2028 | USD 163.2 million |
Growth rate | 15.7% (CAGR from 2020 to 2028) |
Largest segment | Oral |
Fastest growing segment | Injectable |
Historical data | 2017 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Topical, Injectable, Oral |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Oral was the largest segment with a revenue share of 52.96% in 2020. Horizon Databook has segmented the Mexico atopic dermatitis drugs market based on topical, injectable, oral covering the revenue growth of each sub-segment from 2017 to 2028.
Mexico is a prominent market for atopic dermatitis treatments in Latin America. Due to a large population, incidence of atopic dermatitis is also magnified in Mexico. Healthcare institutions have undertaken initiatives to spread awareness about early diagnosis of diseases among citizens through healthcare camps.
However, the exact epidemiological information is highly variable, ranging from 2% for severe atopic dermatitis to 8% for moderate cases. Moreover, high cost of novel products is anticipated to act as a market restraint in this region, owing to its price-sensitive nature and economic weakness, as compared to developed economies such as the U.S.
The inefficient system for drug approval by regulatory committee COFEPRIS is a prime reason for delays in drug launches and approvals. For instance, the average number of days required for Mexican patients to access newly launched novel medications is 1,500 days, which is a significant factor demonstrating slow penetration rate.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Mexico atopic dermatitis drugs market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account